UB30:LSE:LSE-UBS MSCI Emerging Markets UCITS (USD)

ETF | Others |

Last Closing

USD 114.595

Change

-0.56 (-0.48)%

Market Cap

N/A

Volume

500.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-1.75 (-0.94%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-3.13 (-2.62%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.02 (-0.12%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.12 (+0.87%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.45 (+0.63%)

USD 266.08B
0QZO:LSE 0QZO

-1.75 (-1.83%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.04 (-0.13%)

USD 208.06B
0QZ3:LSE Qualcomm Inc.

-1.75 (-1.04%)

USD 202.26B
0R24:LSE Intel Corp.

-0.81 (-3.45%)

USD 196.14B

ETFs Containing UB30:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.70% 69% C- 68% D+
Dividend Return 2.28% 65% D 82% B
Total Return 14.99% 76% C+ 73% C
Trailing 12 Months  
Capital Gain 23.67% 69% C- 68% D+
Dividend Return 2.51% 62% D 80% B-
Total Return 26.18% 73% C 72% C
Trailing 5 Years  
Capital Gain 16.55% 39% F 52% F
Dividend Return 6.42% 62% D 75% C
Total Return 22.97% 42% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 2.34% N/A N/A 47% F
Dividend Return 3.50% N/A N/A 50% F
Total Return 1.16% N/A N/A 76% C+
Risk Return Profile  
Volatility (Standard Deviation) 20.51% N/A N/A 48% F
Risk Adjusted Return 17.04% N/A N/A 51% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike